Patient Guide: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 39 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT05870748
Status: TERMINATED
Condition: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Phase: PHASE2, PHASE3

Find a Study Location Near You

This study is available at 39 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Tucson, Arizona
  • Daly City, California
  • Washington, District of Columbia
  • • And 36 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily